Hyperthermia Blog

What's New, What's News, What's Happening


The Journal of the American Medical Association (JAMA) just published a 10 year patient follow-up to a phase III clinical study on a Soft Tissue Sarcoma Study.

STS Infographic thumb

With Invited Commentary - Technological Advances, Biologic Rationales, and the Associated Success of Chemotherapy With Hyperthermia in Improved Outcomes in Patients With Sarcoma by Mark W. Dewhirst, DVM, PhD; David Kirsch, MD, PhD

Under the organization of the European Society of Hyperthermic Oncology the study was conducted in 9 centers located in Germany, Norway, Austria and the United States using the BSD-2000 Deep Regional Hyperthermia System. This study enrolled 365 soft tissue sarcoma patients (18-70 years old) that were matched and entered into a double blind study. One group received neoadjuvant chemotherapy consisting of doxorubicin, ifosfamide, and etoposide [CT] treatment and the other group received the same chemotherapy along with a course of hyperthermia [HT].

For non-clinicians, we have done our best to provide the salient points in the above info-graphic. The full article can be found on the JAMA website here.

We feel that the results are astonishing. The HEADLINE: chemotherapy plus hyperthermia equals better results and extended life. #heatmatters

Recent Blogs

The Pyrexar Blog is an Opinion Editorial written by Drew Wilkens, Vice President of Digital Content Marketing. We strive to provide factual information and rebuttal or corrections are welcome. Please send your comments to marketing@pyrexar.com